Individual patient data meta-analysis of 16 phase 3 trials (11 883 adults with rheumatoid arthritis): higher BMI was associated with poorer ACR20 response to JAK inhibitors (adjusted RR 0·78 for class 3 obesity vs healthy weight); no BMI gradient on placebo.
Meta-analysisn = 11,883
Bechman et al. Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials